证券代码：688336 证券简称：三生国健 公告编号：2025-045 三生国健药业（上海）股份有限公司 关于 2025 年中期利润分配方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 三生国健药业（上海）股份有限公司（以下简称"公司"） 2025 年中期拟每 10 股派发现金红利人民币 0.33 元（含税），不进 行资本公积转增股本，不送红股。 本次利润分配以实施权益分派股权登记日登记的总股本为基 数，具体日期将在权益分派实施公告中明确。 在实施权益分派的股权登记日前公司总股本发生变动的，拟 维持分配总额不变，相应调整每股分配比例，并将另行公告具体调 整情况。 本次利润分配方案已经公司第五届董事会第十一次会议、第 五届监事会第七次会议审议通过，尚需提交公司 2025 年第五次临时 股东大会审议。 一、利润分配方案内容 根据公司 2025 年半年度财务报告（未经审计），2025 半年度 公司实现归属于上市公司股东的净利润为人民币 19,032.24 万元， 截至 2025 年 6 月 30 日，公 ...

证券代码：688336 证券简称：三生国健 公告编号：2025-050 三生国健药业（上海）股份有限公司 第五届董事会第十一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 三生国健药业(上海)股份有限公司（以下简称"公司"）第五届 董事会第十一次会议通知于 2025 年 8 月 18 日以电话、电子邮件、专 人送达等方式发出。会议于 2025 年 8 月 29 日以现场和通讯结合表决 的方式举行。会议应到董事 7 名，实到董事 7 名。会议由董事长 LOU JING 先生主持，本次会议的召集与召开程序、出席会议人员资格及 议事和表决程序符合《中华人民共和国公司法》和《三生国健药业（上 海）股份有限公司章程》（以下简称"《公司章程》"）的有关规定。 会议决议合法、有效。 二、董事会会议审议情况 （一）审议通过了《关于补选独立董事并调整董事会专门委员会 委员的议案》 根据《上市公司独立董事管理办法》及《上海证券交易所科创板 股票上市规则》等相关规定，独立董事在同一家上市公司连续任职时 间 ...

Core Viewpoint - The report highlights the financial performance and strategic developments of Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. for the first half of 2025, emphasizing significant revenue growth, increased net profit, and advancements in drug development, particularly in the field of autoimmune diseases. Financial Performance - The company achieved a revenue of RMB 642.01 million, representing a 7.61% increase compared to RMB 596.62 million in the same period last year [4] - The net profit attributable to shareholders reached RMB 190.32 million, a substantial increase of 46.96% from RMB 129.51 million year-on-year [4] - The net cash flow from operating activities was RMB 187.73 million, up 33.95% from RMB 140.15 million in the previous year [4] - Basic earnings per share increased to RMB 0.31, a rise of 47.62% from RMB 0.21 [4] Research and Development - R&D expenses increased by 25.53%, with R&D costs accounting for 36.48% of revenue, reflecting the company's commitment to innovation [4][9] - The company has made significant progress in its clinical pipeline, with multiple core autoimmune drug projects advancing to later clinical stages [10] Market and Industry Trends - The global autoimmune disease market is projected to grow from USD 138.9 billion in 2024 to USD 192.3 billion by 2032, with biologics expected to account for 82.4% of the market [6] - In China, the autoimmune disease market is anticipated to reach USD 6.6 billion in 2025, growing at a rate of 29.4% year-on-year, with biologics comprising 51.4% of the market [8] - The company is positioned to benefit from the increasing prevalence of autoimmune diseases and the shift towards biologics and targeted therapies [7][8] Strategic Developments - The company entered a landmark licensing agreement with Pfizer, marking a significant milestone in the global positioning of Chinese pharmaceutical companies [7][9] - This agreement includes a non-refundable upfront payment of USD 1.25 billion and potential milestone payments totaling up to USD 4.8 billion, showcasing the value of Chinese innovation in the global market [9] Clinical Advancements - The company has submitted an NDA for its anti-IL-1β monoclonal antibody and has several projects progressing through clinical trials, including anti-IL-17A and anti-IL-4Rα monoclonal antibodies [10] - These advancements indicate the company's strong pipeline and its potential to address unmet clinical needs in the autoimmune disease space [10]

Core Viewpoint - Sanofi Guojian Pharmaceutical (Shanghai) Co., Ltd. reported a significant increase in revenue and profit for the first half of 2025, but faces challenges in drug development and market competition [1][2]. Financial Performance - The company's total revenue for the first half of 2025 was RMB 64,201.34 million, representing a 7.61% increase compared to RMB 59,661.97 million in the same period last year [4]. - The total profit for the period was RMB 18,621.83 million, a 34.56% increase from RMB 13,838.6 million year-on-year [4]. - The net profit attributable to shareholders was RMB 15,722.72 million, reflecting a 24.64% increase from RMB 12,614.51 million in the previous year [4]. - The basic earnings per share increased by 47.62% to RMB 0.31 from RMB 0.21 [4]. Research and Development - The company is increasing its investment in research and development, particularly in antibody drug development, which is expected to lead to higher R&D expenses in the future [2]. - The proportion of R&D expenses relative to revenue is anticipated to grow, potentially resulting in losses if R&D costs exceed profits from commercialized products [2]. Dividend Distribution - The company plans to distribute a cash dividend of RMB 0.33 per share (including tax) to all shareholders, amounting to a total of RMB 20,353,931.17 (including tax), which represents 10.69% of the net profit attributable to shareholders for the first half of 2025 [2]. Market Environment - The expansion of drug procurement policies and the initiation of biosimilar drug procurement may introduce uncertainties regarding the sales revenue growth of the company's main products [2].

证券代码：688336 证券简称：三生国健 公告编号：2025-045 三生国健药业（上海）股份有限公司 一、利润分配方案内容 根据公司 2025 年半年度财务报告（未经审计），2025 半年度 公司实现归属于上市公司股东的净利润为人民币 19,032.24 万元， 截至 2025 年 6 月 30 日，公司母公司报表中期末未分配利润为人民 币 239,831.98 万元。经董事会决议，公司 2025 半年度拟以实施权 益分派股权登记日登记的总股本为基数分配利润。本次利润分配方 案如下： 关于 2025 年中期利润分配方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 三生国健药业（上海）股份有限公司（以下简称"公司"） 行资本公积转增股本，不送红股。 ? 本次利润分配以实施权益分派股权登记日登记的总股本为基 数，具体日期将在权益分派实施公告中明确。 ? 在实施权益分派的股权登记日前公司总股本发生变动的，拟 维持分配总额不变，相应调整每股分配比例，并将另行公告具体调 整情况。 ? 本次利润分配方 ...

三生国健药业（上海）股份有限公司 募集资金管理制度 第一章 总则 第六条 保荐机构或者独立财务顾问应当按照《证券发行上市保荐业务管理 办法》 《上市规则》、本制度的规定，对公司募集资金的管理和使用履行持续督导 职责，公司应当予以配合。 第一条 为了规范三生国健药业（上海）股份有限公司（以下简称"公司"） 募集资金的管理和使用，保护投资者的权益，依照《中华人民共和国公司法》 （以 下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、 《上海证券交易所科创板股票上市规则》（以下简称"《上市规则》"）、《上 海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》《上市公司募 集资金监管规则》等有关法律法规及规范性文件的规定，结合公司实际情况，特 制定本制度。 第二条 本制度适用于公司通过发行股票或者其他具有股权性质的证券，向 投资者募集并用于特定用途的资金监管，但不包括公司为实施股权激励计划募集 的资金监管。 第三条 公司募集资金应当专款专用。公司使用募集资金应当符合国家产业 政策和相关法律法规，践行可持续发展理念，履行社会责任，原则上应当用于主 营业务，有利于增强公司竞争能力和创新 ...

Core Viewpoint - The internal audit system of Sanofi (Shanghai) Co., Ltd. aims to enhance management and supervision of internal departments, subsidiaries, and significant affiliates, ensuring compliance with laws and regulations while improving audit quality [1][2]. Group 1: Internal Audit Definition and Objectives - Internal audit is defined as an evaluation activity conducted by internal personnel to assess the effectiveness of internal controls, risk management, and the authenticity of financial information [2][3]. - The objectives of internal control include compliance with laws, safeguarding assets, and ensuring the accuracy and completeness of information disclosure [3][4]. Group 2: Internal Audit Department Structure - The company has established an independent internal audit department that reports directly to the board's audit committee [3][5]. - The internal audit department must have a minimum of three dedicated audit personnel, with the head being a full-time position nominated by the audit committee [3][6]. Group 3: Audit Responsibilities - The internal audit department is responsible for evaluating the completeness and effectiveness of internal control systems across the company and its subsidiaries [5][10]. - It must conduct audits on financial data, ensuring legality, compliance, and authenticity, including financial reports and performance forecasts [5][10]. Group 4: Audit Procedures - The internal audit process includes planning, notifying the audited unit, collecting evidence, and drafting audit reports [8][9]. - Audit reports must be submitted within ten days after the audit's conclusion, allowing the audited unit to provide feedback [9][10]. Group 5: Internal Control Evaluation - The internal audit department is required to submit an annual internal control evaluation report to the audit committee, detailing the effectiveness of internal controls [10][11]. - If significant deficiencies or risks are identified, the audit committee must be promptly informed [11][12]. Group 6: Compliance and Reporting - The company must disclose any significant internal control deficiencies or risks to the stock exchange and provide details on corrective measures taken [11][12]. - The internal audit department must audit significant external investments, asset purchases, and guarantees to ensure compliance with regulations [12][13]. Group 7: Training and Accountability - The internal audit department is responsible for training and evaluating audit personnel to enhance their professional skills [33][34]. - Any misconduct by audit personnel, such as leaking confidential information or providing false reports, will result in disciplinary actions [34][35].

General Principles - The rules are established to protect the legal rights of shareholders and ensure the proper functioning of the shareholders' meeting in accordance with relevant laws and regulations [1][2][3] - The shareholders' meeting is the highest authority of the company and has specific powers defined by law and the company's articles of association [1][2] Shareholders' Meeting Types - There are two types of shareholders' meetings: annual and temporary [2] - The annual meeting must be held within six months after the end of the previous fiscal year, while temporary meetings can be called under specific circumstances within two months [2][3] Proposals and Notifications - Shareholders holding more than 1% of shares can propose agenda items for the meeting, and proposals must be submitted in writing [7][8] - Notifications for the annual meeting must be sent 20 days in advance, while notifications for temporary meetings must be sent 15 days in advance [9][10] Meeting Procedures - The meeting must be held at the company's registered address or another designated location, and it should be conducted in a manner that ensures order and compliance with legal requirements [21][22] - The meeting must include a record of attendees, proposals discussed, and voting results [20][21] Voting and Resolutions - Voting is conducted by registered shareholders, and each share carries one vote unless otherwise specified [15][16] - Resolutions can be classified as ordinary or special, with different thresholds for approval: ordinary resolutions require a simple majority, while special resolutions require two-thirds of the votes [16][17] Execution of Resolutions - The board of directors is responsible for executing the resolutions passed at the shareholders' meeting, and any violations of laws or regulations can lead to invalidation of the resolutions [58][59][60] Amendments to Rules - The rules may be amended if they conflict with changes in laws or the company's articles of association, and such amendments must be approved by the shareholders' meeting [63][64]

Core Viewpoint - The company has completed the commitment of fundraising investment for certain projects and plans to permanently supplement its working capital with the remaining funds, which is expected to enhance the efficiency of fund utilization and support its operational activities [1][6][7]. Fundraising Basic Situation - The company was approved to publicly issue 61,621,142 shares at a price of RMB 28.18 per share, raising a total of RMB 1,736,483,781.56, with the net amount after deducting underwriting fees and other expenses being RMB 1,736,483,781.56 [1][2]. Fundraising Investment Plan - The company has outlined its fundraising investment plan in accordance with its prospectus and subsequent announcements, detailing the allocation of funds to various projects, including new drug development and digital factory construction [2][3]. Fund Usage and Surplus Situation - As of August 29, 2025, the company has completed the committed investments for the "new drug development project for autoimmune and ophthalmic diseases" and the "innovation antibody drug industrialization and digital factory construction project," with other fundraising projects concluded [3][4]. Reasons for Fund Surplus - The surplus in fundraising is attributed to effective cost control and management during project execution, leading to lower investment costs. Additionally, the company has generated investment income from temporarily idle funds [4][5]. Surplus Fund Usage Plan - The company plans to permanently supplement its working capital with RMB 7,029.08 million of surplus funds, which will be used for daily operational activities to enhance cash flow and economic efficiency [5][6]. Approval Procedures - The board of directors and the supervisory board have approved the plan to use surplus funds, confirming that it aligns with the company's development strategy and does not harm the interests of shareholders [6][7].

Meeting Overview - The seventh meeting of the fifth Supervisory Board of Sanofi Health (Shanghai) Co., Ltd. was held on August 29, 2025, with all procedures complying with relevant laws and regulations [1] Resolutions Passed - The Supervisory Board unanimously approved the proposal to abolish the Supervisory Board and amend the Articles of Association, transferring its powers to the Audit Committee of the Board of Directors [1] - The Supervisory Board approved the 2025 semi-annual report and summary, confirming compliance with legal and internal regulations, and ensuring the accuracy and completeness of the disclosed information [2] - The Supervisory Board approved the mid-term profit distribution plan for 2025, which considers the company's operational status and future funding needs, and agreed to submit it for shareholder meeting approval [3] - The Supervisory Board approved a special report on the management and actual use of raised funds for the first half of 2025, confirming compliance with relevant regulations [4] - The Supervisory Board approved the proposal to permanently supplement working capital with surplus raised funds from completed projects, emphasizing the efficient use of funds and alignment with the company's operational plans [5]